Century Therapeutics (IPSC) Interest Expenses (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Interest Expenses data on file, last reported at $69.2 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 17342.57% year-over-year to $69.2 million in Q1 2026; TTM through Mar 2026 was $69.2 million, a 5356.82% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, down 99.48% from the prior year.
• Interest Expenses for Q1 2026 stood at $69.2 million, up from $6000.0 in the prior quarter.
• Over the last five years, Interest Expenses for IPSC reached as high as $192.2 million in Q4 2024 and fell as low as -$46000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $34.2 million across 5 years, with a median of $514000.0 in 2023.
• Across the five-year window, Interest Expenses slumped 114.84% in 2023 and jumped 417989.13% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $310000.0 in 2022, then slumped by 114.84% to -$46000.0 in 2023, then soared by 417989.13% to $192.2 million in 2024, then tumbled by 100.0% to $6000.0 in 2025, then soared by 1154016.67% to $69.2 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $69.2 million in Q1 2026, $6000.0 in Q4 2025, and $21.4 million in Q3 2025.